Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(04): 216-230
DOI: 10.1055/s-0040-1712832
Original Article

Molecular and Functional Basis of Cystic Fibrosis in Indian Patients: Genetic, Diagnostic and Therapeutic Implications

Rajendra Prasad
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

ABSTRACT

Cystic fibrosis (CF, MIM#219700) is a common autosomal recessive disorder among Caucasians, which was considered as rare disease for Indian population. CF is caused due to presence of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. In this study, we established a spectrum of mutations from both classical CF as well as from infertile male patients with congenital absence of vas deferens (CAVD). In Indian classical CF patients, we reported 14 previously known and eight novel mutations, viz. 3986-3987 delC, 876-6 del4, 1792 InsA, L69H, S158N, Q493L, 1530L and E1329Q. The frequency of delta 508 was found to be 27%. Absolute linkage between delta 508 and KM19-GATT TUB9-M470V-T854T haplotype predicts a relatively recent appearance of delta 508 mutations in Indian population. The CFTR gene analysis in CAVD infertile males documented 13 different CFTR gene mutations and 1 intronic variant that led to aberrant splicing. P.Phe 508 del (n= 16) and p.Arg 117 His (n=4) were among the common severe forms of CFTR mutations identified. The IVS-8-T5 allele (mild form of mutations) was formed with an allele frequency of 28.3%. Eight novel mutations were also found in the CFTR gene from our patient cohort. We also investigated whether genetic modifiers, viz. transforming growth factor (TGF-β) and endothelial receptor type A (EDNRA) of CF lung disease also predispose to CAVD in association with CFTR mutations, which were associated with the CAVD phenotype.

Functional characterization of identified 11 novel CFTR gene mutations disclosed that a significant reduction in channel activity for L69H and S549N mutants in CFTR expressing cells was observed whereas impaired CFTR protein maturation was noticed only in L69H substitute CFTR. CFTR correctors (VX809) rescued the defect due to L69H mutation, which is evidenced from detection of C band in L69H mutant expressing cells pre-treated with VX809. The chloride channel activity in S549N and L69H mutant CFTR was also restored in presence of CFTR potentiators VX770.

Above findings confirms heterogeneity of CFTR mutations in Indian classical and non-classical CF patients. They may help in developing a strategy to develop counseling and therapeutic approach for CF patients in India.

Keywords

Cystic fibrosis - genetic mutation - CFTR

DR. V.R. KHANOLKAR ORATION delivered during the NAMSCON 2018 held at the Mahatma Gandhi Medical College & Research Institute, Puducherry.




Publication History

Article published online:
09 May 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM (2009). Association between carrier screening and incidence of cystic fibrosis. JAMA 302: 2573-2579.
  • 2 Prasad R, Sharma H, Kaur G (2010). Molecular basis of cystic fibrosis disease: an Indian perspective. Indian J Clin Biochem 25: 335-341.
  • 3 Bhakoo ON, Kumar R, Walia BNS (1968). Mucoviscidosis of the lung. Report of a case. Indian J Pediatr 35:183-185.
  • 4 Prasad R, Marwaha RK, Kaur G, Walia BNS (1998). Spectrum of biochemical genetic diseases in North India. Med Sci Res 26: 455-456.
  • 5 Rowe SM, Miller S, Sorscher EJ (2005). Cystic fibrosis. N Engl J Med 352: 1992-2001.
  • 6 Chillon M, Casals T, Mercier B, et al (1995). Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332: 1475-1480.
  • 7 Riordan JR, Rommens JM, Kerem B, et al (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
  • 8 Rommens JM, Iannuzzi MC, Kerem B, et al (1989). Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245: 1059-1065.
  • 9 Zielenski J, Rozmahel R, Bozon D, et al (1991). Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 10: 214-228.
  • 10 Bear CE, Li CH, Kartner N, et al (1992). Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68: 809-818.
  • 11 Hyde SC, Emsley P, Hartshorn MJ, et al (1990). Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346: 362-365.
  • 12 Short DB, Trotter KW, Reczek D, et al (1998). An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J Biol Chem 273: 19797-19801.
  • 13 Castellani C, Cuppens H, Macek M Jr, et al (2008). Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7: 179-196.
  • 14 Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL (1999). C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 274: 21873-21877.
  • 15 Anguiano A, Oates RD, Amos JA, et al (1992). Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA 267: 1794-1797.
  • 16 Chillón M, Casals T, Mercier B, et al (1995). Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332: 1475-1480.
  • 17 Drumm ML, Konstan MW, Schluchter MD, et al (2005). Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353: 1443-1453.
  • 18 Darrah R, McKone E, O'Connor C, et al (2010). EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics 41: 71-77.
  • 19 Goraca A (2002). New views on the role of endothelin (minireview). Endocr Regul 36: 161-167.
  • 20 Solomon GM, Marshall SG, Ramsey BW, Rowe SM (2015). Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatr Pulmonol 50: S3-S13.
  • 21 Morral N, Nunes V, Casals T, et al (1993). Microsatellite haplotypes for cystic fibrosis: mutation frameworks and evolutionary tracers. Hum Mol Genet 2: 1015-2102.
  • 22 Dodge JA (2015). A millennial view of cystic fibrosis. Dev Period Med 19: 9-13.
  • 23 Farrell PM, Rosenstein BJ, White TB, et al (2008). Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153: S4-S14.
  • 24 Rosenstein BJ, Cutting GR (1998). The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132: 589-595.
  • 25 Gibson LE, Cooke RE (1959). A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23: 545-549.
  • 26 Rowe MS, Miller SBS, Sorcher EJ (2005). Cystic Fibrosis. N Engl J Med 352: 1991-2001.
  • 27 Wallis C (1997). Diagnosing cystic fibrosis: blood, sweat, and tears. Arch Dis Child 76: 85-88.
  • 28 Veeze HJ, Sinaasappel M, Bijman J, Bouquet J, de Jonge HR (1991). Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 101: 398-403.
  • 29 Walters MP, Kelleher J, Gilbert J, Littlewood JM (1990). Clinical monitoring of steatorrhoea in cystic fibrosis. Arch Dis Child 65: 99-102.
  • 30 Sharma N, Singh M, Kaur G, Thapa BR, Prasad R (2009). Identification and characterization of CFTR gene mutations in Indian CF patients. Ann Hum Genet 73: 26-33.
  • 31 Bowler IM, Estlin EJ, Littlewood JM (1993). Cystic fibrosis in Asians. Arch Dis Child 68: 120-122.
  • 32 Kabra M, Kabra SK, Ghosh M, et al (2000). Is the spectrum of mutations in Indian patients with cystic fibrosis different? Am J Med Genet 93: 161-163.
  • 33 Mei-Zahav M, Durie P, Zielenski J, et al (2005). The prevalence and clinical characteristics of cystic fibrosis in South Asian Canadian immigrants. Arch Dis Child 90: 675-679.
  • 34 Morral N, Nunes V, Casals T, et al (1993). Microsatellite haplotypes for cystic fibrosis: mutation frameworks and evolutionary tracers. Hum Mol Genet 2: 1015-1022.
  • 35 Shastri SS, Kabra M, Kabra SK, Pandey RM, Menon PS (2008). Characterisation of mutations and genotype-phenotype correlation in cystic fibrosis: experience from India. J Cyst Fibros 7: 110-115.
  • 36 Kilinç MO, Ninis VN, Dağli E, et al (2002). Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. Am J Med Genet 113: 250-257.
  • 37 Sharma H, Mavuduru RS, Singh SK, Prasad R (2014). Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers. Mol Hum Reprod 20: 827-835.
  • 38 Sharma N, Singh M, Acharya N, et al (2008). Implication of the cystic fibrosis transmembrane conductance regulator gene in infertile family members of Indian CF patients. Biochem Genet 46: 847-856.
  • 39 Sharma N, Acharya N, Singh SK, Singh M, Sharma U, Prasad R (2009). Heterogenous spectrum of CFTR gene mutations in Indian patients with congenital absence of vas deferens. Hum Reprod 24: 1229-1236.
  • 40 Casals T, Bassas L, Egozcue S, et al (2000). Heterogeneity for mutations in the CFTR gene and clinical correlations in patients with congenital absence of the vas deferens. Hum Reprod 15: 1476-8143.
  • 41 Castellani C, Cuppens H, Macek M Jr, et al (2008). Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7: 179-196.
  • 42 Mak V, Zielenski J, Tsui LC, et al (1999). Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. J Am Med Assoc 281: 2217-2224.
  • 43 Berinardino ALF, Lima CA, Zatz M (2003). Analysis of mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in patients with obstructive azoospermia. Genet Mol Biol 26: 1-3.
  • 44 Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
  • 45 Hocher B, Schwarz A, Fagan KA, et al (2000). Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 23: 19-26.
  • 46 Ruest LB, Xiang X, Lim KC, Levi G, Clouthier DE (2004). Endothelin-A receptor -dependent and -independent signaling pathways in establishing mandibular identity. Development 131: 4413-4423.
  • 47 Pla P, Larue L (2003). Involvement of endothelin receptors in normal and pathological development of neural crest cells. Int J Dev Biol 47: 315-325.
  • 48 Moore SW, Zaahl MG (2007). Association of endothelin-beta receptor (EDNRB) gene variants in anorectal malformations. J Pediatr Surg 42: 1266-1270.
  • 49 Yi S, Pierucci-Alves F, Schultz BD (2013). Transforming growth factor-β1 impairs CFTR-mediated anion secretion across cultured porcine vas deferens epithelial monolayer via the p38 MAPK pathway. Am J Physiol Cell Physiol 305: C867-C876.
  • 50 Sharma H, Jollivet Souchet M, Callebaut I, Prasad R, Becq F (2015). Function, pharmacological correction and maturation of new Indian CFTR gene mutations. J Cyst Fibros 14: 34-41.
  • 51 Cheng SH, Gregory RJ, Marshall J, et al (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834.
  • 52 Ward CL, Omura S, Kopito RR (1995). Degradation of CFTR by the ubiquitinproteasome pathway. Cell 83: 121-127.
  • 53 Ramsey BW, Davies J, McElvaney NG, et al (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663-1672.
  • 54 Yu H, Burton B, Huang CJ, et al (2012). Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11: 237-245.
  • 55 Wilschanski M, Miller LL, Shoseyov D, et al (2011). Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38: 59-69.
  • 56 Rowe SM, Borowitz DS, Burns JL, et al (2012). Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 67: 882-890.
  • 57 Okiyoneda T, Veit G, Dekkers JF, et al (2013). Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 9: 444-454.
  • 58 Ramsey BW, Davies J, McElvaney NG, et al (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663-1672.
  • 59 Solomon GM, Marshall SG, Ramsey BW, Rowe SM (2015). Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatr Pulmonol 50: S3-S13.
  • 60 De Boeck K, Vermeulen F, Dupont L (2017). The diagnosis of cystic fibrosis. Presse Med 46: e97-e108.
  • 61 Fajac I, Wainwright CE (2017). New treatments targeting the basic defects in cystic fibrosis. Presse Med 46: e165-e175.